Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12989012 | 0.87 | GPR119 (0.42) | CHRM1CHRM2CHRM3CHRM5NR1H2 | |
| SCHEMBL12128829 | 0.84 | CHRM1 (0.46) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL12292725 | 0.83 | CHRM1 (0.46) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL12988993 | 0.81 | RAB9A (0.43) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL12084215 | 0.81 | CHRM1 (0.45) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL12989011 | 0.80 | CHRM1 (0.38) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL12086318 | 0.80 | CHRM1 (0.44) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL12017210 | 0.80 | CHRM2 (0.68) | CHRM1CHRM2CHRM3NR1H2GPR119 | |
| SCHEMBL12988771 | 0.79 | CHRM1 (0.37) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL12988976 | 0.79 | CHRM1 (0.38) | CHRM1CHRM2CHRM3CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| WO-2007076070-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CHRM1 6/4885CHRM2 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.